-

Longhorn Vaccines and Diagnostics to Present at The Allen D. Leman Swine Conference

BETHESDA & GAITHERSBURG, Md.--(BUSINESS WIRE)--Longhorn Vaccines and Diagnostics LLC, a One Health and One World company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today announced that Jerry Torrison, DVM, PhD, Senior Vice President of Animal Health, will present at the Allen D. Leman Swine Conference, being held in the St. Paul River Center, Minnesota, on Sept. 17 – 20, 2022.

Dr. Torrison will be giving the Morrison Lectureship, named in honor of Dr. Bob Morrison, his PhD advisor, for his work in the areas of swine disease epidemiology and factors that drive economics and productivity in the swine industry.

Presentation Title: FADs,..Are We Ready (Together)?
Presenter: Jerry Torrison, DVM, PhD, Senior Vice President of Animal Health at Longhorn Vaccines and Diagnostics
Abstract Title: Foreign Animal Disease (FAD) Response
Session Date: Sept. 20, 2022
Session Time: 9:00 – 10:00am CST
Session Location: The St. Paul River Centre, Minnesota

About Longhorn Vaccines and Diagnostics LLC

Longhorn Vaccines and Diagnostics LLC is a One Health company based in Maryland that is developing vaccines and diagnostic tools for worldwide public health concerns and to prevent future pandemics. Since its inception in 2006, Longhorn has focused on developing vaccines and diagnostic tools that can impact a pandemic on a global scale and at all socio-economic levels. Since pandemics flow between humans and animals, Longhorn caters to both in order to surveil, diagnose, prevent and treat the next infectious disease.

Longhorn’s core product, PrimeStore® Molecular Transport Medium (MTM), is a patented, FDA cleared, state-of-the-art ambient temperature molecular diagnostic collection and transport device that can help governments, global health organizations, and drug manufacturers improve the diagnosis and treatment of highly infectious diseases such as Influenza, SARS-CoV-2, and Mycobacterium tuberculosis (TB). Unlike standard devices for collecting and transporting virus samples, PrimeStore® MTM is the first molecular transport device that can safely deactivate pathogens and stabilize RNA and DNA, allowing enhanced point of care and ambient temperature transport for laboratory based molecular testing and characterization.

Contacts

Longhorn Vaccines and Diagnostics LLC
Jeffrey Fischer
Email: jeff@lhnvd.com

Media
Alexis Feinberg – ICR Westwicke PR
Email:  LonghornPR@icrinc.com

Longhorn Vaccines and Diagnostics LLC


Release Versions

Contacts

Longhorn Vaccines and Diagnostics LLC
Jeffrey Fischer
Email: jeff@lhnvd.com

Media
Alexis Feinberg – ICR Westwicke PR
Email:  LonghornPR@icrinc.com

More News From Longhorn Vaccines and Diagnostics LLC

Longhorn Vaccines & Diagnostics' PrimeStore® MTM Validated with New Data for Large-Scale, Global TB Screening

GAITHERSBURG, Md.--(BUSINESS WIRE)--Longhorn Vaccines & Diagnostics (“Longhorn”), a One Health company developing antibodies and diagnostic tools for global public health and zoonosis concerns, today announced compelling new data validating the utility of various swab samples processed with PrimeStore® MTM for tuberculosis (TB) detection in both pediatric clinical settings and large-scale community screening. The findings were divided into two presentations and presented by TB and viral inf...

Longhorn Vaccines & Diagnostics to Present Data on Large-Scale TB Screening with PrimeStore® MTM at The Union World Conference on Lung Health 2025

GAITHERSBURG, Md.--(BUSINESS WIRE)--Longhorn Vaccines & Diagnostics (“Longhorn”), a One Health company developing antibodies and diagnostic tools for global public health and zoonosis concerns, announced today that the University of Pretoria will present two studies around alternative sample tuberculosis (TB) screening using PrimeStore® MTM, an FDA-cleared sample medium for inactivating both RNA and DNA, at The Union World Conference on Lung Health 2025. The abstract presentations will high...

Longhorn Vaccines and Diagnostics to Present Late-Breaking Poster at ESCMID 2025 on LHNVD-303 to Treat and Prevent Antimicrobial Resistance

GAITHERSBURG, Md.--(BUSINESS WIRE)--Longhorn Vaccines and Diagnostics (“Longhorn”) today announced it will present a late-breaking poster at the 6th ESCMID Conference on Vaccines supporting the breath of a single, conserved-target antibody to address the bacteria associated with antimicrobial resistance (AMR) and inflammation from gram-positive and gram-negative pathogens. The presentation will feature the company’s anti-peptidoglycan (PGN) monoclonal antibody, the core of LHNVD-303, for the pr...
Back to Newsroom